cancer prevention
Conditions
Interventions
blood collection for cell culture and blood tests.
Administration of cultured cells for the treatment 3 times.
Sponsors
Takimoto Rishu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Who meet the following criteria based on a medical checkup conducted within the past six months: - Urinary cell metabolic marker (ALA-PDS) of 3,000 or higher for men and 3,750 or higher for women - No malignant tumors. - No severe liver or kidney dysfunction. - No pathological arrhythmia (2)Have risk factors for cancer and desire for receiving immune-cell therapy. (3)Be > 18 of age when obtaining the informed consent. (4)Be determined to be appropriate by the doctor in charge. (5)Provide written informed consent.
Exclusion criteria
Exclusion criteria: (1)Be diagnosed with cancer. (2)Desire to receive the immune-cell therapy for the treatment of any allergic disease. (3)Be an allotransplant recipient. (4)Have a history or sign of interstitial pneumonia. (5)Have an active autoimmune disease. (6)Have inflammatory bowel syndrome (7)Have sleep apnea syndrome (8)Having diabetes mellitus. (9)Having bowel problems. (10)Be a female who is pregnant, nursing, or of childbearing potential. (11)A subject 70 years of age and above must be carefully considered for the risk of an autoimmune disease to enroll in this study. (12)Receive antibiotics within past 1 month (13)Be determined to be inappropriate by the doctor in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological response | — |
Countries
Japan
Contacts
Public ContactTakashi Kamigaki
Koshikai, Non-profit Medical Corporation
Outcome results
None listed